JP2016505039A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505039A5
JP2016505039A5 JP2015553775A JP2015553775A JP2016505039A5 JP 2016505039 A5 JP2016505039 A5 JP 2016505039A5 JP 2015553775 A JP2015553775 A JP 2015553775A JP 2015553775 A JP2015553775 A JP 2015553775A JP 2016505039 A5 JP2016505039 A5 JP 2016505039A5
Authority
JP
Japan
Prior art keywords
phenyl
metformin
glp1r agonist
glp1r
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015553775A
Other languages
English (en)
Japanese (ja)
Other versions
JP6445459B2 (ja
JP2016505039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011394 external-priority patent/WO2014113357A1/en
Publication of JP2016505039A publication Critical patent/JP2016505039A/ja
Publication of JP2016505039A5 publication Critical patent/JP2016505039A5/ja
Application granted granted Critical
Publication of JP6445459B2 publication Critical patent/JP6445459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015553775A 2013-01-17 2014-01-14 Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用 Active JP6445459B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361753567P 2013-01-17 2013-01-17
US61/753,567 2013-01-17
PCT/US2014/011394 WO2014113357A1 (en) 2013-01-17 2014-01-14 Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders

Publications (3)

Publication Number Publication Date
JP2016505039A JP2016505039A (ja) 2016-02-18
JP2016505039A5 true JP2016505039A5 (https=) 2017-02-16
JP6445459B2 JP6445459B2 (ja) 2018-12-26

Family

ID=50030537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015553775A Active JP6445459B2 (ja) 2013-01-17 2014-01-14 Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用

Country Status (13)

Country Link
US (1) US20150313908A1 (https=)
EP (1) EP2945618B1 (https=)
JP (1) JP6445459B2 (https=)
KR (1) KR102165434B1 (https=)
CN (1) CN104968341B (https=)
AU (1) AU2014207748B2 (https=)
CA (1) CA2896308C (https=)
EA (1) EA201591123A1 (https=)
ES (1) ES2687083T3 (https=)
IL (1) IL239714A0 (https=)
MX (1) MX366685B (https=)
SG (2) SG10201704716XA (https=)
WO (1) WO2014113357A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200364A (en) 2017-09-22 2023-12-21 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof
EP3790549A1 (en) * 2018-05-08 2021-03-17 vTv Therapeutics LLC Therapeutic uses of glp1r agonists
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor
WO2021196951A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
EP4272733A4 (en) * 2020-12-31 2024-07-10 Dong Kook Pharm. Co., Ltd PHARMACEUTICAL COMPOSITION CONTAINING TADALAFIL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF HAVING A NOVEL DISSOLUTION RATE
CN120187750A (zh) 2022-09-21 2025-06-20 瑞泽恩制药公司 治疗肥胖、糖尿病和肝功能障碍的方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
WO2007056387A2 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide
US7727983B2 (en) * 2008-03-07 2010-06-01 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
JP5755217B2 (ja) * 2009-03-30 2015-07-29 トランステック・ファーマ，エルエルシー 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
WO2011031620A1 (en) 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
TR201809460T4 (tr) * 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
US20130040878A1 (en) * 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients

Similar Documents

Publication Publication Date Title
JP2016505039A5 (https=)
TWI329014B (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3receptor antagonist/inverse agonist
JP2014528474A5 (https=)
JP2019517542A5 (https=)
JP2015523397A5 (https=)
JP2009542699A5 (https=)
JP2017528507A5 (https=)
JP2016510326A5 (https=)
JP6445459B2 (ja) Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用
JP2022031813A (ja) １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法
JP2020529440A5 (https=)
EP4233913A3 (en) Improved bromocriptine formulations
TWI606848B (zh) 包含格米列汀與美氟明的組合藥物及其製備方法
JP2014511365A5 (https=)
JP2018500297A (ja) 脂肪代謝の調節に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用
JPWO2021045159A5 (https=)
JP2017509628A5 (https=)
JP2020536068A5 (https=)
JP2015510947A5 (https=)
JP2019528290A5 (https=)
JP2009506043A5 (https=)
JPWO2016047800A1 (ja) 脂質異常症治療剤
EP3796901A2 (en) Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease
Harano et al. Proposal of Inappropriate Insulin Syndrome Screened with Standard Cookie Meal, A Possible Accelerating and Common Factor for Corona 19, Metabolic Syndrome and Obesity and its Clinical Significance
JP2019529554A5 (https=)